Acetaminophen ER + Placebo

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dental Pain

Conditions

Dental Pain

Trial Timeline

Oct 1, 2013 → Apr 1, 2014

About Acetaminophen ER + Placebo

Acetaminophen ER + Placebo is a phase 2 stage product being developed by Johnson & Johnson for Dental Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01960114. Target conditions include Dental Pain.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01960114Phase 2Completed

Competing Products

20 competing products in Dental Pain

See all competitors
ProductCompanyStageHype Score
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
77
Sodium Fluoride DentifriceJohnson & JohnsonPre-clinical
23
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
77
Acetaminophen (ACE) (1000 mg) + Commercial ACE (1000 mg) + Commercial Ibuprofen (IBU) (400 mg) + Placebo + Placebo + PlaceboJohnson & JohnsonPhase 2
52
2 mg nicotine gum + 4 mg nicotine gumJohnson & JohnsonApproved
85
acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsuleJohnson & JohnsonPhase 3
77
Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassiumNovartisPhase 3
77
Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral + ARRY-371797, p38 inhibitor; oral + Celecoxib, COX-2 inhibitor; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oralPfizerPhase 2
51
Pregabalin + Alprazolam + PlaceboPfizerPhase 2
51
Prototype (AN0128 Toothpaste)PfizerPhase 1
32
PF-05089771 + PF-05089771 + PF-05089771 + IbuprofenPfizerPhase 2
51
ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oralPfizerPhase 2
51
PF-04531083 + PF-04531083 + IbuprofenPfizerPhase 2
51
Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + PlaceboBayerPhase 3
74
XPF-001 + placeboXenon PharmaceuticalsPhase 2
49
N1539 + placebo + N1539 + N1539 + MotrinAlkermesPhase 2
49
Comparator: etoricoxib + Comparator: ibuprofen + Comparator: acetaminophen + codeine + Comparator: placeboOrganonPhase 3
72
Full Dose Strength + Quarter dose strength + Half dose strength + Acetaminophen standard dose + Ibuprofen low dose + Ibuprofen high dose + PlaceboAFT PharmaceuticalsPhase 2
44
Maxigesic 325 + Acetaminophen + Ibuprofen + PlaceboAFT PharmaceuticalsPhase 3
69
C16G2 GelArmata PharmaceuticalsPhase 2
44